Observational cohort study in older women with early breast cancer: Use of radiation therapy and impact on health-related quality of life and mortality.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
08 2021
Historique:
received: 21 02 2021
revised: 07 06 2021
accepted: 09 06 2021
pubmed: 20 6 2021
medline: 6 8 2021
entrez: 19 6 2021
Statut: ppublish

Résumé

Radiotherapy reduces in-breast recurrence risk in early breast cancer (EBC) in older women. This benefit may be small and should be balanced against treatment effect and holistic patient assessment. This study described treatment patterns according to fitness and impact on health-related quality-of-life (HRQoL). A multicentre, observational study of EBC patients aged ≥ 70 years, undergoing breast-conserving surgery (BCS) or mastectomy, was undertaken. Associations between radiotherapy use, surgery, clinico-pathological parameters, fitness based on geriatric parameters and treatment centre were determined. HRQoL was measured using the European Organisation for the Research and Treatment of Cancer (EORTC) questionnaires. In 2013-2018 2811 women in 56 UK study centres underwent surgery with a median follow-up of 52 months. On multivariable analysis, age and tumour risk predicted radiotherapy use. Among healthier patients (based on geriatric assessments) with high-risk tumours, 534/613 (87.1%) having BCS and 185/341 (54.2%) having mastectomy received radiotherapy. In less fit individuals with low-risk tumours undergoing BCS, 149/207 (72.0%) received radiotherapy. Radiotherapy effects on HRQoL domains, including breast symptoms and fatigue were seen, resolving by 18 months. Radiotherapy use in EBC patients ≥ 70 years is affected by age and recurrence risk, whereas geriatric parameters have limited impact regardless of type of surgery. There was geographical variation in treatment, with some fit older women with high-risk tumours not receiving radiotherapy, and some older, low-risk, EBC patients receiving radiotherapy after BCS despite evidence of limited benefit. The impact on HRQoL is transient.

Sections du résumé

BACKGROUND
Radiotherapy reduces in-breast recurrence risk in early breast cancer (EBC) in older women. This benefit may be small and should be balanced against treatment effect and holistic patient assessment. This study described treatment patterns according to fitness and impact on health-related quality-of-life (HRQoL).
METHODS
A multicentre, observational study of EBC patients aged ≥ 70 years, undergoing breast-conserving surgery (BCS) or mastectomy, was undertaken. Associations between radiotherapy use, surgery, clinico-pathological parameters, fitness based on geriatric parameters and treatment centre were determined. HRQoL was measured using the European Organisation for the Research and Treatment of Cancer (EORTC) questionnaires.
RESULTS
In 2013-2018 2811 women in 56 UK study centres underwent surgery with a median follow-up of 52 months. On multivariable analysis, age and tumour risk predicted radiotherapy use. Among healthier patients (based on geriatric assessments) with high-risk tumours, 534/613 (87.1%) having BCS and 185/341 (54.2%) having mastectomy received radiotherapy. In less fit individuals with low-risk tumours undergoing BCS, 149/207 (72.0%) received radiotherapy. Radiotherapy effects on HRQoL domains, including breast symptoms and fatigue were seen, resolving by 18 months.
CONCLUSION
Radiotherapy use in EBC patients ≥ 70 years is affected by age and recurrence risk, whereas geriatric parameters have limited impact regardless of type of surgery. There was geographical variation in treatment, with some fit older women with high-risk tumours not receiving radiotherapy, and some older, low-risk, EBC patients receiving radiotherapy after BCS despite evidence of limited benefit. The impact on HRQoL is transient.

Identifiants

pubmed: 34146616
pii: S0167-8140(21)06593-2
doi: 10.1016/j.radonc.2021.06.021
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

166-176

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Nicolò Matteo Luca Battisti (NML)

Department of Medicine, Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK & Breast Cancer Research Division, The Institute of Cancer Research, London, UK.

Matthew Q Hatton (MQ)

Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, UK.

Malcolm W R Reed (MWR)

Brighton and Sussex Medical School, Brighton, UK.

Esther Herbert (E)

Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, UK.

Jenna L Morgan (JL)

Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.

Michael Bradburn (M)

Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, UK.

Richard Simcock (R)

Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.

Stephen J Walters (SJ)

Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, UK.

Karen A Collins (KA)

College of Health, Wellbeing and Life Sciences, Department of Allied Health Professions, Sheffield Hallam University, Sheffield, UK.

Sue E Ward (SE)

Department of Health Economics and Decision Science, School for Health and Related Research (ScHARR), University of Sheffield, UK.

Geoffrey R Holmes (GR)

Department of Health Economics and Decision Science, School for Health and Related Research (ScHARR), University of Sheffield, UK.

Maria Burton (M)

College of Health, Wellbeing and Life Sciences, Department of Allied Health Professions, Sheffield Hallam University, Sheffield, UK.

Kate J Lifford (KJ)

Division of Population Medicine, Cardiff University, Cardiff, UK.

Adrian Edwards (A)

Division of Population Medicine, Cardiff University, Cardiff, UK.

Thompson G Robinson (TG)

Department of Cardiovascular Sciences and NIHR Biomedical Research Centre, University of Leicester, Cardiovascular Research Centre, Leicester, UK.

Charlene Martin (C)

Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.

Tim Chater (T)

Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, UK.

Kirsty J Pemberton (KJ)

Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, UK.

Alan Brennan (A)

Department of Health Economics and Decision Science, School for Health and Related Research (ScHARR), University of Sheffield, UK.

Kwok Leung Cheung (K)

School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

Annaliza Todd (A)

Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.

Riccardo A Audisio (RA)

University of Gothenberg, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden.

Juliet Wright (J)

Brighton and Sussex Medical School, Brighton, UK.

Tracy Green (T)

Yorkshire and Humber Consumer Research Panel, Sheffield, UK.

Deirdre Revell (D)

Yorkshire and Humber Consumer Research Panel, Sheffield, UK.

Jacqui Gath (J)

Yorkshire and Humber Consumer Research Panel, Sheffield, UK.

Kieran Horgan (K)

Department of Breast Surgery, Bexley Cancer Centre, St James's University Hospital, Leeds, UK.

Chris Holcombe (C)

Liverpool University Hospitals Foundation Trust, Liverpool, UK.

Matthew C Winter (MC)

Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, UK.

Jay Naik (J)

Pinderfields Hospital, Mid Yorkshire NHS Foundation Trust, Wakefield, UK.

Rishi Parmeshwar (R)

University Hospitals of Morecambe Bay, Royal Lancashire Infirmary, Lancaster, UK.

Margot A Gosney (MA)

Royal Berkshire NHS Foundation Trust, Reading, UK.

Alastair M Thompson (AM)

Department of Surgery, Baylor College of Medicine, Houston, USA.

Lynda Wyld (L)

Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK. Electronic address: l.wyld@sheffield.ac.uk.

Alistair Ring (A)

Department of Medicine, Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK & Breast Cancer Research Division, The Institute of Cancer Research, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH